Sugi Predict

Sugi Predict / Compounds / SCHEMBL3738754

SCHEMBL3738754

SCHEMBL3738754

Cc1ccc(-c2ccccc2CC(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 2/20 0.53
▸ FFAR4 Q5NUL3 2/20 0.53
▸ PTGS1 P23219 2/20 0.53
▸ AKR1B1 P15121 1/20 0.50
▸ PTGDR2 Q9Y5Y4 1/20 0.48
▸ LMNA P02545 3/20 0.48
▸ POLB P06746 1/20 0.48
▸ KMT2A Q03164 1/20 0.47
▸ SUCNR1 Q9BXA5 1/20 0.47
▸ PTGS2 P35354 2/20 0.47
▸ PTGER1 P34995 1/20 0.47
▸ PTGER4 P35408 1/20 0.47
▸ PTGER3 P43115 1/20 0.47
▸ PTGER2 P43116 1/20 0.47
▸ TDP1 Q9NUW8 2/20 0.44
▸ PDCD1 Q15116 1/20 0.44
▸ CD274 Q9NZQ7 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ABCC4 O15439 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL28588588 0.87 PTGS1 (0.57) FFAR1FFAR4PTGS1AKR1B1PTGDR2
SCHEMBL5961842 0.87 PTGS1 (0.59) PTGS1AKR1B1PTGDR2LMNAKMT2A
SCHEMBL538512 0.87 KMT2A (0.60) FFAR1FFAR4PTGS1AKR1B1PTGDR2
SCHEMBL5045725 0.86 FFAR1 (0.47) FFAR1FFAR4PTGS1PTGDR2LMNA
SCHEMBL28594606 0.85 KMT2A (0.58) FFAR1FFAR4PTGS1AKR1B1PTGDR2
SCHEMBL27701716 0.85 KMT2A (0.58) FFAR1FFAR4PTGS1AKR1B1PTGDR2
Hydrochloric Acid SCHEMBL11895689 0.85 KMT2A (0.58) FFAR1FFAR4PTGS1AKR1B1PTGDR2
Ammonia Solution, Strong SCHEMBL27926479 0.85 KMT2A (0.58) FFAR1FFAR4PTGS1AKR1B1PTGDR2
SCHEMBL29512995 0.85 KMT2A (0.58) FFAR1FFAR4PTGS1AKR1B1PTGDR2
SCHEMBL8645744 0.85 PTGS1 (0.55) PTGS1AKR1B1PTGDR2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844065-B1 LURE COMPOSITION ATTRATEC GMBH (DE) 2021-01-06 — — EP claimed
EP-1817031-B1 CASPASE-10 INHIBITORS FOR PREVENTION AND TREATMENT OF RETINOPATHY MERCK PATENT GMBH (DE) 2014-05-21 — — EP claimed
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors MERCK PATENT GESELLSCHAFT (DE) 2008-10-16 — — US claimed
EP-1817031-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS Merck Patent GmbH (DE) 2007-08-15 — — EP claimed
WO-2006058592-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS MERCK PATENT GMBH (DE) 2006-06-08 — — WO claimed
US-12630783-B2 Muguet type fragrance compounds SYMRISE AG (DE) 2026-05-19 — — US disclosed
US-12577495-B2 Fragrance mixtures containing 1-(4,4-dimethylcyclohexen-1-yl) ethanon SYMRISE AG (DE) 2026-03-17 — — US disclosed
EP-3684898-B1 METHOD FOR PRODUCING AN ACTIVE SUBSTANCE WAFER SYMRISE AG (DE) 2025-04-30 — — EP disclosed
US-12103935-B2 Seco-ambraketals SYMRISE AG (DE) 2024-10-01 — — US disclosed
EP-4214211-B1 SECO-AMBRAKETALS SYMRISE AG (DE) 2024-07-10 — — EP disclosed
US-11993760-B2 2-furyl- and 2-thienyl-substituted di- and tetrahydropyrans for use as aroma chemicals BASF SE (DE) 2024-05-28 — — US disclosed
EP-4359496-A1 AROMA OR FRAGRANCE COMPOSITIONS, COMPRISING 4-METHYLHEPTAN-3-ONE, AND METHODS FOR PRODUCING THEM Symrise AG (DE) 2024-05-01 — — EP disclosed
US-7348035-B2 Cyclodextrin particle SYMRISE GMBH & CO. KG (DE) 2008-03-25 — — US disclosed
EP-1817031-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS Merck Patent GmbH (DE) 2007-08-15 — — EP disclosed
WO-2006058592-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS MERCK PATENT GMBH (DE) 2006-06-08 — — WO disclosed
US-20040234479-A1 Cyclodextrin particle SYMRISE GMBH & CO. KG (DE) 2004-11-25 — — US disclosed
EP-0695552-B1 Method of perfuming conveyances and perfuming article therefor CUBE CO LTD F (JP) 1999-09-22 — — EP disclosed
US-5593635-A Method for perfuming conveyances and perfuming article therefor F. CUBE CO. LTD. (JP) 1997-01-14 — — US disclosed
EP-0695552-A1 Method of perfuming conveyances and perfuming article therefor F. Cube Co., Ltd. (JP) 1996-02-07 — — EP disclosed
US-5274104-A N-substituted heterocyclic derivatives useful in the treatment of cardiovascular disorders ELF SANOFI, A FRENCH CORP. (FR) 1993-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577495-B2 Fragrance mixtures containing 1-(4,4-dimethylcyclohexen-1-yl) ethanon ALG3, FAAH, FAAH2 FFAR1 86/4885FFAR4 154/4885PTGS1 566/4885
US-12630783-B2 Muguet type fragrance compounds MGAT1, RFT1, CPT1A FFAR1 681/4885FFAR4 475/4885PTGS1 438/4885
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors CASP10, CASP1, CASP5 FFAR1 624/4885FFAR4 860/4885PTGS1 564/4885
US-11993760-B2 2-furyl- and 2-thienyl-substituted di- and tetrahydropyrans for use as aroma chemicals TRPA1, TAS2R5, TAS2R3 FFAR1 636/4885FFAR4 455/4885PTGS1 566/4885
US-12103935-B2 Seco-ambraketals AREG, CUTA, TAAR5 FFAR1 213/4885FFAR4 209/4885PTGS1 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.